Ap19
AMENDMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) |
J.P. Morgan Securities LLC |
Company dealt in |
Willis Towers Watson plc |
Class of relevant security to which the dealings being disclosed relate (Note 2) |
US$0.000304635 ordinary shares |
Date of dealing |
25 November 2020 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
Long |
Short |
||||
|
Number |
|
(%) |
Number |
|
(%) |
(1) Relevant securities |
2,385,722 1.85 |
2,329,679 1.81 |
||||
(2) Derivatives (other than options) |
2,228,227 1.73 |
2,261,851 1.75 |
||||
(3) Options and agreements to purchase/sell |
|
|
||||
Total |
4,613,949 3.58 |
4,591,530 3.56 |
||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase (New Borrow)
Purchase
Sale |
33,200
1 100 100 100 63 100 27 200 7 3 1 100 1 20 300 800 363 3 1 101 4 200 1,411 5 56 1 80 9 2 1 3 1 22 3 1
1 400 200 100 240 100 100 500 63 1 1 14 1 100 1 2 100 1 11 1 83 300 800 363 1 23 101 3 42 2,500 112 125 3 14 111 18 12 10 58 |
NA
205.8300 206.1800 206.2700 206.3400 206.5900 206.9400 207.0000 207.0150 207.4010 207.4400 207.4800 207.6200 207.6700 207.7096 208.1133 208.2360 208.3135 208.8867 209.0000 209.1500 209.3400 209.4350 209.4400 209.4700 209.5000 209.5300 209.6200 209.9322 210.0100 210.0600 210.0667 210.0850 210.1955 210.2800 210.3400
205.5100 205.5738 205.6100 206.1800 206.2619 206.2700 206.3400 206.3660 206.5900 207.0000 207.3600 207.4010 207.4900 207.5600 207.6200 207.6700 207.7800 207.9300 207.9391 207.9700 207.9799 208.1133 208.2360 208.3135 208.6200 208.7043 209.0000 209.2900 209.3513 209.4400 209.5000 209.5964 209.6100 209.7871 209.8893 210.0903 210.1625 210.2100 210.2324 |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD |
Nature of transaction (Note 6) |
Number of relevant securities (Note 7) |
Price per unit (USD) (Note 5) |
Equity Swap |
Short |
800 |
208.2360 |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure |
30 November 2020 |
Contact name |
Alwyn Basch |
Telephone number |
0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected |
N/A |
If a connected EFM, state nature of connection (Note 10) |
N/A |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.